Buprenorphine Medicine 07 June 2022 Extended indication Treatment of moderate to severe chronic pain in patients with opioid dependence. Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Buprenorphine Domain Neurological disorders Reason of inclusion Indication extension IND Main indication Pain Extended indication Treatment of moderate to severe chronic pain in patients with opioid dependence. Current proprietary name Already available biosimilars / generics Proprietary name Buvidal Manufacturer Camurus Portfolio holder Mechanism of action Receptor agonist Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Unknown Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date November 2021 Expected Registration September 2022 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/07/21/gvs-advies-subcutaan-buprenorfine-buvidal Additional remarks Er zijn 7 verschillende doseringen beschikbaar: 4 doseringen zijn geschikt voor de wekelijkse toediening en 3 doseringen zijn geschikt voor de maandelijkse toediening. De apotheekinkoopprijs (AIP) is voor alle wekelijkse doseringen gelijk, dit komt neer op €87. Voor alle maandelijkse doseringen komt de AIP uit op €375,88. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks